Universitatsspital Bern
Welcome,         Profile    Billing    Logout  
 10 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pabst, Thomas
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Hourglass Jul 2024 - Dec 2024 : Data for RRMM
Active, not recruiting
2
177
Europe, Canada, US, RoW
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
08/24
02/25
OV-AML-1231, NCT06384261: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Recruiting
2
120
Europe, Canada, US
Cusatuzumab, OV-1001, Venetoclax, Azacitidine
OncoVerity, Inc.
Leukemia, Myeloid, Acute
01/27
06/27
NCT03187210: Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas

Suspended
1/2
20
Europe
Brentuximab Vedotin, BeEAM Regimen
Insel Gruppe AG, University Hospital Bern, Mundipharma Medical Company
Lymphoma
11/23
11/24
OMNIA-2, NCT05641324: A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma

Terminated
1
4
Europe
ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab
Anaveon AG
Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease, Hematologic Diseases
07/23
07/23
Investigator, Madrigal
MAESTRO-NASH, NCT03900429 / 2018-004012-22: A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

Active, not recruiting
3
1759
Europe, Canada, US, RoW
MGL-3196, Resmetirom, Placebo, Liver Biopsy
Madrigal Pharmaceuticals, Inc.
NASH - Nonalcoholic Steatohepatitis
01/28
01/28
NCT04951219: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Recruiting
3
1000
US
Resmetirom, MGL-3196
Madrigal Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease
03/26
04/26
NCT04643795: Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Completed
1
87
US
MGL-3196
Madrigal Pharmaceuticals, Inc.
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
08/21
08/21

Download Options